These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 14624100)

  • 1. Impact of diagnostic markers on early antifungal therapy.
    Jones BL; McLintock LA
    Curr Opin Infect Dis; 2003 Dec; 16(6):521-6. PubMed ID: 14624100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preemptive antifungal therapy: still a way to go.
    Maertens J; Deeren D; Dierickx D; Theunissen K
    Curr Opin Infect Dis; 2006 Dec; 19(6):551-6. PubMed ID: 17075330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical assessment of issues in the diagnosis of invasive aspergillosis.
    Klont RR; Meis JF; Verweij PE
    Clin Microbiol Infect; 2001; 7 Suppl 2():32-7. PubMed ID: 11525216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
    Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and treatment of invasive fungal diseases in neutropenic patients.
    Almyroudis NG; Segal BH
    Curr Opin Infect Dis; 2009 Aug; 22(4):385-93. PubMed ID: 19506476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the molecular and serological diagnosis of invasive fungal infection in haemato-oncology patients.
    McLintock LA; Jones BL
    Br J Haematol; 2004 Aug; 126(3):289-97. PubMed ID: 15257700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive mycoses: diagnostic challenges.
    Ostrosky-Zeichner L
    Am J Med; 2012 Jan; 125(1 Suppl):S14-24. PubMed ID: 22196205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of fungal infection: new technologies for the mycology laboratory.
    Alexander BD
    Transpl Infect Dis; 2002; 4 Suppl 3():32-7. PubMed ID: 12486790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory diagnosis and therapy of invasive fungal infections.
    Willinger B
    Curr Drug Targets; 2006 Apr; 7(4):513-22. PubMed ID: 16611039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in diagnostic testing.
    Verweij PE
    Med Mycol; 2005 May; 43 Suppl 1():S121-4. PubMed ID: 16110803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive diagnostic approach using galactomannan, targeted β-d-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients.
    Ceesay MM; Desai SR; Berry L; Cleverley J; Kibbler CC; Pomplun S; Nicholson AG; Douiri A; Wade J; Smith M; Mufti GJ; Pagliuca A
    Br J Haematol; 2015 Jan; 168(2):219-29. PubMed ID: 25179933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular techniques in the diagnosis of deep and systemic mycosis.
    Springer J; Einsele H; Loeffler J
    Clin Dermatol; 2012; 30(6):651-6. PubMed ID: 23068152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting.
    White PL; Linton CJ; Perry MD; Johnson EM; Barnes RA
    Clin Infect Dis; 2006 Feb; 42(4):479-86. PubMed ID: 16421791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
    Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients.
    Einsele H; Loeffler J
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():37-45. PubMed ID: 18430128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monitoring and prophylaxis].
    Yoshida M
    Nihon Ishinkin Gakkai Zasshi; 2001; 42(4):205-10. PubMed ID: 11704746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early signals of systemic mycoses--guidelines for therapeutic decisions?].
    Bernhardt H; Knoke M
    Mycoses; 2004; 47 Suppl 1():60-5. PubMed ID: 15667367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of pan-fungal PCR assay and Aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk paediatric cancer patients.
    El-Mahallawy HA; Shaker HH; Ali Helmy H; Mostafa T; Razak Abo-Sedah A
    Med Mycol; 2006 Dec; 44(8):733-9. PubMed ID: 17127630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early diagnosis of fungal infection in immunocompromised patients.
    Barnes RA
    J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i3-6. PubMed ID: 18063601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triggers for driving treatment of at-risk patients with invasive fungal disease.
    Drgona L; Colita A; Klimko N; Rahav G; Ozcan MA; Donnelly JP
    J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii17-iii24. PubMed ID: 24155142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.